Thermo Fisher Scientific Inc.

Thermo Fisher Scientific Inc. is the world's largest pure-play life sciences tools, diagnostics, and pharma services company, generating $44.6 billion in revenue in fiscal 2025 across four segments that collectively span the laboratory bench, the manufacturing plant, and the clinical trial site. Its more than 125,000 employees serve roughly 400,000 customers in pharmaceutical and biotechnology companies, hospitals, universities, and government agencies — a footprint that makes the company a reasonable proxy for global R&D and healthcare spending.

This is a story about a compounding portfolio assembled through three decades of disciplined M&A, now at a scale where the question shifts from "can it grow?" to "can it grow enough to justify the price?" The file turns on whether the sum of organic momentum in pharma and biotech, the integration of two large recent acquisitions, and the steady earnings power of the legacy franchise is worth roughly 24× trailing EBITDA in an environment where the end-market recovery is still building.

TMO is not a bet on any single technology cycle. It is a bet on the structure of the industry it serves — and on management's ability to keep compounding capital at mid-teens returns on invested capital in a business where the top line rarely grows more than mid-single digits organically.